Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience.

Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience. Abstract Text:

BACKGROUND: Gliadel (polifeprosan 20 with carmustine [BCNU] implant) is commonly used for local delivery of BCNU to high-grade gliomas after resection and is associated with increased survival. Various complications of Gliadel wafers have been reported but not consistently reproduced. We set out to characterize Gliadel-associated morbidity in our 10-year experience with Gliadel wafers for treatment of malignant glioma. METHODS: We retrospectively reviewed records of 1013 patients undergoing craniotomy for resection of malignant brain astrocytoma (World Health Organization grade III/IV disease). Perioperative morbidity occurring within 3 months of surgery was assessed for patients and compared between patients receiving versus not receiving Gliadel wafer. Overall survival was assessed for all patients. RESULTS: A total of 1013 craniotomies were performed for malignant brain astrocytoma. A total of 288 (28%) received Gliadel wafer (250 glioblastoma multiforme (GBM), 38 anaplastic astrocytoma/anaplastic oligodendroglioma (AA/AO), 166 primary resection, 122 revision resection). Compared with the non-Gliadel cohort, patients receiving Gliadel were older (55 +/- 14 vs. 50 +/- 17, P = .001) and more frequently underwent gross total resection (75% vs 36%, P < .01) but otherwise similar. Patients in Gliadel versus non-Gliadel cohorts had similar incidences of perioperative surgical site infection (2.8% vs. 1.8%, P = .33), cerebrospinal fluid leak (2.8% vs. 1.8%, P = .33), meninigitis (.3% vs. .3%, P = 1.00), incisional wound healing difficulty (.7% vs. .4%, P = .63), symptomatic malignant edema (2.1% vs. 2.3%, P = 1.00), 3-month seizure incidence (14.6% vs. 15.7%, P = .65), deep-vein thrombosis (6.3% vs. 5.2%, P = .53), and pulmonary embolism (PE) (4.9% vs. 3.7%, P = .41). For patients receiving Gliadel for GBM, median survival was 13.5 months after primary resection (20% alive at 2 years) and 11.3 months after revision resection (13% alive at 2 years). For patients receiving Gliadel for AA/AO, median survival was 57 months after primary resection (66% alive at 2 years) and 23.6 months after revision resection (47% alive at 2 years). CONCLUSION: In our experience, use of Gliadel wafer was not associated with an increase in perioperative morbidity after surgical treatment of malignant astrocytoma.

Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Annals of surgical oncology

VOLUME: 15

Page Numbers: 2887-93

Journal Abbreviation: Ann. Surg. Oncol.

ISSN: 1534-4681

DAY: 18

MONTH: 07

YEAR: 2008

Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9420840

Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience.

AFFILIATION: Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ann Surg Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Use of Gliadel BCNU Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience Related Publications

• Angiogenesis and blood-brain barrier breakdown modulate CT contrast enhancement: an experimental study in a rabbit brain-tumor model.
• Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities.
• Blinded comparison of computer-aided detection with human second reading in screening mammography: the importance of the question and the critical numbers game.
• Case of Paroxysmal Hemoglobinuria Treated with Salvarsan.
• Editorial for "Mammography Screening of Women in Their Forties : the impact of changes in screening guidelines".
• Effects of different cryoprotectants and carbohydrates on freezing of matured and unmatured bovine oocytes.
• Electrofusion parameters for mouse two-cell embryos.
• Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol.
• Fertilization of bovine oocytes induced solely with combined laser microbeam and optical tweezers.
• Hemorrhagic vestibular schwannoma: an unusual clinical entity. Case report.
• Human VNTR sequences in porcine HTF-islands.
• Human renal 11beta-hydroxysteroid dehydrogenase 1 functions and co-localizes with COX-2.
• Infarcted lactating adenoma presenting as a rapidly enlarging breast mass.
• Influence of beta-carotene on fertility in rabbits when using embryo transfer programs.
• Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas.
• Lobular carcinoma in situ of the breast presenting as a mass.
• Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model.
• Mammographic appearance of lymphedema in a TRAM-reconstructed breast.
• PRESIDENT'S ADDRESS ANNUAL MEETING LOS ANGELES COUNTY MEDICAL ASSOCIATION DECEMBER 15, 1921-GOVERNMENTAL ACTIVITIES AND TENDENCIES IN THE HEALTH FIELD.
• Pitfall of MR in a patient with spinal ependymoma and drop metastasis.
• Stereotactic vacuum-assisted breast biopsy: an unusual cause of Mondor's disease.
• THE PLACE OF PATHOLOGY IN THE PRACTICE OF MEDICINE.
• The porcine PHIcDNA linked to the halothane gene detects a NotI RFLP in normal and malignant hyperthermia susceptible pigs.
• Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience.
• Using gene transcription patterns (bar coding scans) to guide wound debridement and healing.
• Variable expression of 11beta Hydroxysteroid dehydrogenase (11beta-HSD) isoforms in vascular endothelial cells.
• [Embryo transfer in swine in relation to a gene transfer program]
• [Production of chimeras by embryo microsurgery and their possible application in cattle breeding]
• [The structure of eukaryotic genes]
• [Treatment of knee osteoarthritis]